Hydration Pharmaceuticals sharply reduced Hydralyte LLC’s US operating loss in the September quarter after cutting costs and refocusing marketing. But weaker September trading, stock-outs, limited cash and an ununderwritten entitlement offer leave the turnaround unfinished.
The Hydration Pharmaceuticals Company (ASX:HPC) has sharply reduced its operating losses, with Hydralyte LLC recording its first monthly EBITDA profit in August. The group remains loss-making overall, but improved margins and a lower cost base are beginning to show in the numbers.